Comparative pharmacological studies of melatonin receptors: MT1, MT2 and MT3/QR2. tissue distribution of MT3/QR2

Biochemical Pharmacology

Volumn 61, Issue 11, 2001, Pages 1369-1379

  Nosjean, Olivier ^a   Nicolas, Jean Paul ^a   Klupsch, Frederique ^b   Delagrange, Philippe ^c   Canet, Emmanuel ^a   Boutin, Jean A ^a  

^a INSTITUT DE RECHERCHES SERVIER   (France)

^b Inst Chim Pharmaceut   (France)

^c IRIS Institut de Recherches Internationales Servier   (France)

Author keywords

Inhibitors; Ligands; Melatonion receptor; MT1; MT2; MT3; Quinone reductase; Tissue distribution

Indexed keywords

2 IODO N BUTANOYL 5 METHOXYTRYPTAMINE; 2 IODOMELATONIN; 2 IODOMETHOXY CARBONYLAMINO N ACETYLTRYPTAMINE; 2 PHENYLMELATONIN; 4 PHENYL 2 PROPIONAMIDOTETRALINE; 5 METHOXY N CYCLOPROPANOYLTRYPTAMINE; 6 CHLOROMELATONIN; ACETAMIDE DERIVATIVE; ACRIDINE ORANGE; BENZYLNICOTINAMIDE; CARBAMIC ACID DERIVATIVE; DIHYDROBENZYLNICOTINAMIDE; IODINE 125; LUZINDOLE; MELATONIN; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR; MELATONIN DERIVATIVE; MELATONIN RECEPTOR; MELATONIN RECEPTOR 3; N [2 (5 CARBAMOYLBENZOFURAN 3 YL)ETHYL]ACETAMIDE; N METHYL [1 [2 (ACETYLAMINO)ETHYL]NAPHTHALEN 7 YL]CARBAMATE; N METHYL [3 [2 [(CYCLOPROPYLCARBONYL)AMINO]ETHYL]BENZO[B]FURAN 5 YL]CARBAMATE; N PENTANOYL 2 BENZYLTRYPTAMINE; NICOTINAMIDE DERIVATIVE; PRAZOSIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); ROLIPRAM; TETRALIN DERIVATIVE; TRYPTAMINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING SITE; CATALYSIS; CHEMICAL STRUCTURE; CONTROLLED STUDY; CROSS REACTION; ENZYME ACTIVITY; KIDNEY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; SPECIES DIFFERENCE; TISSUE DISTRIBUTION;

ANIMALS; BINDING, COMPETITIVE; CELLS, CULTURED; CRICETINAE; HUMANS; IODINE RADIOISOTOPES; KINETICS; MELATONIN; MICE; RABBITS; RADIOLIGAND ASSAY; RATS; RECEPTORS, CELL SURFACE; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, MELATONIN; SPECIES SPECIFICITY; TEMPERATURE; TISSUE DISTRIBUTION; TRYPTAMINES;

EID: 0035371006     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(01)00615-3     Document Type: Article

References (41)

1. Redman J.R., Armstrong S.M., Hg K.T. Free-running activity rhythms in the rat entrainment by melatonin . Science. 219:1983;1089-1091.
2. Maestroni G.J. The immunoendocrine role of melatonin. J Pineal Res. 14:1993;1-10.
3. Scalbert E., Guardiola-Lemaître B., Delagrange P. Melatonin and regulation of the cardiovascular system. Therapie. 53:1998;459-465.
4. 1H NMR spectroscopy . Anal Biochem. 142:1984;284-289.
5. 125I-melatonin. FEBS Lett. 197:1986;9-12.
6. Pang S.F., Dubocovich M.L., Brown G.M. Melatonin receptors in peripheral tissues a new era of melatonin research . Biol Signals. 2:1993;177-180.
7. Morgan P.J., Barret P., Howell H.E., Helliwell R. Melatonin receptors localization, molecular pharmacology and physiological significance . Neurochem Int. 24:1994;101-146.
8. Delagrange P., Guardiola-Lemaître B. Melatonin, its receptors, and relationships with biological rhythm disorders. Clin Neuropharmacol. 20:1997;482-510.
9. Reppert S.M., Weaver D.R., Ebisawa T. Cloning and characterization of a mammalian melatonin receptor that mediates reproductive and circadian responses. Neuron. 13:1994;1177-1185.
10. 1b melatonin receptor . Proc Natl Acad Sci USA. 92:1995;8734-8738.
11. Ebisawa T., Karne S., Lerner M.R., Reppert S.M. Expression cloning of a high-affinity melatonin receptor from Xenopus dermal melanophores. Proc Natl Acad Sci USA. 91:1994;6133-6137.
12. Reppert S.M., Weaver D.R. Melatonin madness. Cell. 83:1995;1059-1062.
13. Brydon L., Roka F., Petit L., de Coppet P., Tissot M., Barret P., Morgan P.J., Nanoff C., Strosberg A.D., Jockers R. Dual signaling of human Mel1a melatonin receptors via G(i2), G(i3), and G(q/11) proteins. Mol Endocrinol. 13:1999;2025-2038.
14. Petit L., Lacroix I., de Coppet P., Strosberg A.D., Jockers R. Differential signaling of human Mel1a and Mel1b melatonin receptors through the cyclic guanosine 3′-5′-monophosphate pathway. Biochem Pharmacol. 58:1999;633-639.
15. Dubocovich M.L. Melatonin receptors are there multiple subtypes? Trends Pharmacol Sci. 16:1995;50-56.
16. 125I]iodomelatonin binding sites in hamster brain membranes:pharmacological characteristics and regional distribution. Endocrinology. 122:1988;1825-1833.
17. Pickering D.S., Niles L.P. Pharmacological characterization of melatonin binding sites in Syrian hamster hypothalamus. Eur J Pharmacol. 175:1990;71-77.
18. 2 binding sites . Eur J Pharmacol. 301:1996;159-168.
19. 125I]-melatonin binding sites in Syrian hamster peripheral organs. J Pharmacol Exp Ther. 290:1999;334-340.
20. 3 as the quinone reductase 2. J Biol Chem. 275:2000;31311-31317.
21. Lesieur D, Klupsch F, Guillaumet G, Viaud MC, Langlois M, Bennejean C, Renard P, Delagrange P. International Patent Application WO9958496 (1999).
22. Lowry O.H., Roseborough N.J., Farr A.L., Randall R.J. Protein measurement with the folin phenol reagent. J Biol Chem. 193:1951;265-275.
23. 50) of an enzymatic reaction. Biochem Pharmacol. 22:1973;3099-3108.
24. Dubocovich M.L., Masana M.I., Iacob S., Sauri D.M. Melatonin receptor antagonists that differentiate between the human Mel1a and Mel1b recombinant subtypes are used to assess the pharmacological profile of the rabbit retina ML1 presynaptic heteroreceptor. Arch Pharmacol. 355:1997;365-375.
25. 2 melatonin receptor antagonists block melatonin-mediated phase advances of circadian rhythms. FASEB J. 12:1998b;1211-1220.
26. Beresford I.J.M., Browning C., Starkey S.J., Brown J., Foord S.M., Coughla J., North P.C., Dubocovich M.L., Hagan R.M. GR196429 a non indolic agonist at high-affinity melatonin receptors . J Pharmacol Exp Ther. 285:1998;1239-1245.
27. Acuna-Castroviejo D., Reiter R.J., Menéndez-Pelaez A., Pablos M.I., Burgos A. Characterization of high-affinity melatonin binding sites in purified cell nuclei of rat liver. J Pineal Res. 16:1994;100-112.
28. Hazlerigg D.G., Barrett P., Hastings M.H., Morgan P.J. Are nuclear receptors involved in pituitary responsiveness to melatonin? Mol Cell Endocrinol. 123:1996;53-59.
29. Rafii-El-Idrissi M., Calvo J.R., Harmouch A., Garcia-Maurino S., Guerrero J.M. Specific binding of melatonin by purified cell nuclei from spleen and thymus of the rat. J Neuroimmunol. 86:1998;190-197.
30. Le Gouic S., Atgié C., Viguerie-Bascands N., Hanoun N., Larrouy D., Ambid L., Raimbault S., Ricquier D., Delagrange P., Guardiola-Lemaître B., Pénicaud L., Casteilla L. Characterization of a melatonin binding site in Siberian hamster brown adipose tissue. Eur J Pharmacol. 339:1997;271-278.
31. 3 receptors . Neuropharmacology. 34:1995;1693-1696.
32. Teh M.T., Sugden D. Comparison of the structure-activity relationships of melatonin receptor agonists and antagonists lengthning the N-acyl side-chain has differing effects on potency on Xenopus melanophores . Naunyn Schmiedebergs Arch Pharmacol. 358:1998;522-528.
33. Sugden D., Rowe S.J. 2-iodo-N-butanoyl-5-methoxytryptamine a potent melatonin receptor agonist . Pharmacol Comm. 4:1994;267-276.
34. Depreux P., Lesieur D., Mansour H.A., Morgan P., Howell H.E., Renard P., Caignard D.H., Pfeiffer B., Delagrange P., Guardiola B. Synthesis and structure-activity relationships of novel naphtalenic and bioisosteric related amidic derivatives as melatonin receptor ligands. J Med Chem. 37:1994;3231-3239.
35. Stanaszek W.F., Kellerman D., Brogden R.N., Romankiewicz J.A. Prazosin update. A review of its pharmacological properties and therapeutic use in hypertension and congestive heart failure. Drugs. 25:1993;339-384.
36. Maidorn R.P., Gragoe E.J., Tannock I.F. Therapeutic potential analogues of amiloride:inhibition of the regulation of intracellular pH as a possible mechanism of tumour selective therapy. Br J Cancer. 67:1993;297-303.
37. Schwabe U., Miyake M., Ohga Y., Daly J.W. 4-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone (ZK62711) a potent inhibitor of adenosine cyclic 3′,5′-monophosphate phosphodiesterase in homogenates and tissue slices from rat brain . Mol Pharmacol. 12:1976;900-910.
38. Long DJ, Jaiswal AK. Mouse NRH:quinone oxidoreductase (NQO2): cloning of cDNA and gene- and tissue-specific expression. Gene 252:104-17.
39. Jaiswal AK. Human NAD(P)H:quinone oxidoreductase2. Gene structure, activity, and tissue-specific expression. J Biol Chem 269:14502-8.
40. Zhao Q., Yang X.L., Holtzclaw W.D., Talalay P. Unexpected genetic and structural relationships of a long-forgotten flavoenzyme to NAD(P)H:quinone reductase (DT-diaphorase). Proc Natl Acad Sci USA. 94:1997;1669-1674.
41. Gauer F., Masson-Pévet M., Pévet P. Melatonin receptor density is regulated in rat pars tuberalis and suprachiasmatic nuclei by melatonin itself. Brain Research. 602:1993;153-156.